Antiplatelet combo benefits post-CABG 'durable for five years'

Chinese researchers report five-year outcomes in a trial comparing dual and single antiplatelet therapies

Five-year follow-up of a trial comparing dual and single antiplatelet therapies after elective coronary artery bypass graft surgery shows benefits in patients on the dual regimen persist, researchers report.

preparing a vein for CABG

The results of the extension trial showed a 36-37% reduced incidence of a combination of major adverse cardiovascular events (MACE) in patients who used both ticagrelor and aspirin after their coronary artery bypass graft (CABG) procedure compared with

Latest